Vimarsana
Biggest News Aggregation in the World

Page 3 - Ophthalmic Solution News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ophthalmic Solution. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ophthalmic Solution Today - Breaking & Trending Today

Lupin launches cataract surgery pain reduction drug; share price gains - Vimarsana News

Lupin launches cataract surgery pain reduction drug; share price gains

The share touched a 52-week high of Rs 1,429.95 and a 52-week low of Rs 628.10 on January 5, 2024 and March 31, 2023, respectively.

Lupin obtains FDA OK for generic Bromfenac, tentative nod for generic Invokana - Vimarsana News

Lupin obtains FDA OK for generic Bromfenac, tentative nod for generic Invokana

Generic Bromfenac Ophthalmic Solution is indicated for the treatment of post operative inflammation and reduction of ocular pain in patients who have under gone cataract surgery.

Myopia Market to Grow at a Substantial Growth Rate During the Study Period (2019-2032), Predicts DelveInsight | Leading Companies - Nevakar, Vyluma, Bausch & Lomb, Sydnexis, Ocumension, ORA, LENZ Therapeutics - Vimarsana News

Myopia Market to Grow at a Substantial Growth Rate During the Study Period (2019-2032), Predicts DelveInsight | Leading Companies - Nevakar, Vyluma, Bausch & Lomb, Sydnexis, Ocumension, ORA, LENZ Therapeutics

/PRNewswire/ -- DelveInsight's Myopia Market Insights report includes a comprehensive understanding of current treatment practices, myopia emerging drugs,...

Graft Versus Host Disease Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Assesses DelveInsight | Key Companies - Glia, Incyte, Novartis, GlaxoSmithKline, Pfizer, BMS, Roche, AstraZeneca, Sanofi - Vimarsana News

Graft Versus Host Disease Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Assesses DelveInsight | Key Companies - Glia, Incyte, Novartis, GlaxoSmithKline, Pfizer, BMS, Roche, AstraZeneca, Sanofi

DelveInsight's Graft Versus Host Disease Market...

Alembic, Aurobindo recall drugs in US market - Vimarsana News

Alembic, Aurobindo recall drugs in US market

Alembic Pharmaceuticals and Aurobindo Pharma are recalling products in the US due to manufacturing problems. Alembic is recalling 82,400 bottles of Tobramycin Ophthalmic Solution due to “Failed Impurities/Degradation Specifications.” Meanwhile, Aurobindo Pharma is recalling 48 bottles of Rufinamide Tablets, in both 200 mg and 400 mg doses, due to cGMP (current good manufacturing practice) deviations, USFDA said. The batch was released prior to approval. Rufinamide tablets are used to treat seizure disorders.